HRTX Q4 2020 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M-41.3% YoY

Gross Profit

$11M54.4% margin

Operating Income

-$61M-297.5% margin

Net Income

-$62M-302.3% margin

EPS (Diluted)

$-0.68

QoQ Revenue Growth

+3.2%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$55M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$354M

Total Liabilities

$117M

Stockholders' Equity

$236M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$35M	-41.3%
Gross Profit	$11M	$19M	-41.6%
Operating Income	-$61M	-$59M	-3.3%
Net Income	-$62M	-$58M	-7.5%

Revenue Segments

C I N V A N T I

$20M98%

S U S T O L

$400,0002%